Mallinckrodt Receives US Patent Covering Release Profile Of Xartemis XR

Mallinckrodt has been granted a patent from the US PTO which contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of Xartemis XR (oxycodone hydrochloride+acetaminophen).

Xartemis XR (formerly known as MNK-795), a key driver in Mallinckrodt's near-term pipeline, is an investigational extended-release oral formulation of oxycodone and acetaminophen that has been studied with twice-daily dosing for the management of acute pain in a post-surgical model. If approved, Xartemis XR will be the first oxycodone and acetaminophen combination medication specifically designed with immediate- and extended-release components. The patent, US Patent No. 8,658,631, was issued on February 25.

The release profile of Xartemis XR combines Mallinckrodt-proprietary technology and Depomed's advanced Acuform drug-delivery technology. Between the Mallinckrodt and Depomed patent families, Mallinckrodt believes Xartemis XR will have strong patent protection for its novel features.

Mallinckrodt Receives US Patent Covering Release Profile Of Xartemis XR

Mallinckrodt has been granted a patent from the US PTO which contains composition claims directed to unique design, formulation, pharmacokinetic, and release characteristics of Xartemis XR (oxycodone hydrochloride+acetaminophen).

Xartemis XR (formerly known as MNK-795), a key driver in Mallinckrodt's near-term pipeline, is an investigational extended-release oral formulation of oxycodone and acetaminophen that has been studied with twice-daily dosing for the management of acute pain in a post-surgical model. If approved, Xartemis XR will be the first oxycodone and acetaminophen combination medication specifically designed with immediate- and extended-release components. The patent, US Patent No. 8,658,631, was issued on February 25.

The release profile of Xartemis XR combines Mallinckrodt-proprietary technology and Depomed's advanced Acuform drug-delivery technology. Between the Mallinckrodt and Depomed patent families, Mallinckrodt believes Xartemis XR will have strong patent protection for its novel features.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.